• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?

作者信息

Rubboli Andrea, Lisi Matteo

机构信息

Department of Cardiovascular Diseases - AUSL Romagna, Division of Cardiology, Ospedale S. Maria delle Croci, Viale Randi 5, 48121, Ravenna, Italy.

出版信息

Cardiovasc Drugs Ther. 2019 Aug;33(4):499-500. doi: 10.1007/s10557-019-06886-w.

DOI:10.1007/s10557-019-06886-w
PMID:31077003
Abstract
摘要

相似文献

1
After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
Cardiovasc Drugs Ther. 2019 Aug;33(4):499-500. doi: 10.1007/s10557-019-06886-w.
2
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.AUGUSTUS试验中接受冠状动脉支架置入术的房颤患者的支架内血栓形成
Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
3
Might apixaban be the optimal oral anticoagulant for haemophiliacs with atrial fibrillation?阿哌沙班是否可能是患有心房颤动的血友病患者的最佳口服抗凝剂？
Haemophilia. 2015 Jul;21(4):e338-40. doi: 10.1111/hae.12709. Epub 2015 May 4.
4
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
5
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.急性冠状动脉综合征或经皮冠状动脉介入治疗背景下房颤患者抗血小板和抗凝治疗的管理
Circ Cardiovasc Interv. 2014 Feb;7(1):113-24. doi: 10.1161/CIRCINTERVENTIONS.113.001150.
6
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.阿哌沙班或阿司匹林治疗心房颤动合并近期急性冠状动脉综合征或经皮冠状动脉介入治疗患者的住院情况：来自AUGUSTUS试验的见解
Circulation. 2019 Dec 3;140(23):1960-1963. doi: 10.1161/CIRCULATIONAHA.119.043754. Epub 2019 Sep 25.
7
Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?阿哌沙班（艾乐妥）是替代华法林用于预防房颤患者中风的“理想”抗凝药吗？
S D Med. 2013 Jan;66(1):20-1.
8
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.心房颤动急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗血栓治疗。
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
9
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.阿哌沙班与其他新型口服抗凝药预防心房颤动卒中的成本效益比较。
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.
10
Reasons for nonadherence to the direct oral anticoagulant apixaban for atrial fibrillation.非坚持服用直接口服抗凝药阿哌沙班治疗心房颤动的原因。
J Am Geriatr Soc. 2021 Dec;69(12):3683-3687. doi: 10.1111/jgs.17423. Epub 2021 Aug 27.